- The FDA and Johnson & Johnson (NYSE:JNJ) are close to an announcement that millions of its doses produced at a troubled Baltimore Emergent BioSolutions (NYSE:EBS) can be released, according to The Wall Street Journal.
- The vaccines can be distributed because contamination issues, detailed in an FDA inspection, have been corrected.
- Emergent made headlines back in March after it was reported 15M J&J vaccine doses were contaminated due to human error.
- The newspaper reports that regulators and J&J have tentatively agreed that ~60M vaccine doses will be made available for the U.S. and abroad.
- The Journal also said that about 60M AstraZeneca (NASDAQ:AZN) vaccine doses, manufactured at the same plant, could be made available in the coming weeks as part of a separate agreement with the FDA.
- J&J shares are up 0.1% to $169.05, Emergent shares are up 5.5% to $61, and AstraZeneca shares are up a penny to $56.90 in after-hours trading.